What is HC Wainwright’s Forecast for Nkarta Q4 Earnings?

Nkarta, Inc. (NASDAQ:NKTX) – Analysts at HC Wainwright issued their Q4 2025 earnings per share estimates for shares of Nkarta in a research note issued on Thursday, March 27th. HC Wainwright analyst E. Bodnar anticipates that the company will earn ($0.29) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Nkarta’s current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Nkarta’s FY2029 earnings at ($0.99) EPS.

Nkarta (NASDAQ:NKTX) last announced its quarterly earnings data on Wednesday, March 26th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.06.

Several other analysts also recently weighed in on NKTX. Stifel Nicolaus cut their price target on Nkarta from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price target on shares of Nkarta in a research note on Thursday. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Nkarta has an average rating of “Buy” and a consensus target price of $14.86.

Nkarta Stock Performance

Shares of NASDAQ NKTX opened at $2.00 on Friday. The company has a 50 day simple moving average of $1.99 and a two-hundred day simple moving average of $2.87. Nkarta has a fifty-two week low of $1.31 and a fifty-two week high of $11.84. The company has a market capitalization of $141.14 million, a price-to-earnings ratio of -1.06 and a beta of 0.90.

Insider Activity

In other news, CEO Paul J. Hastings sold 17,378 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total transaction of $38,231.60. Following the completion of the transaction, the chief executive officer now directly owns 319,859 shares of the company’s stock, valued at $703,689.80. The trade was a 5.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 8.70% of the company’s stock.

Institutional Investors Weigh In On Nkarta

A number of hedge funds have recently added to or reduced their stakes in the stock. Jefferies Financial Group Inc. grew its holdings in shares of Nkarta by 901.7% in the fourth quarter. Jefferies Financial Group Inc. now owns 2,504,219 shares of the company’s stock worth $6,236,000 after acquiring an additional 2,254,219 shares during the period. Tang Capital Management LLC boosted its position in Nkarta by 252.9% in the fourth quarter. Tang Capital Management LLC now owns 2,293,719 shares of the company’s stock worth $5,711,000 after purchasing an additional 1,643,719 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Nkarta by 138.7% during the 4th quarter. JPMorgan Chase & Co. now owns 2,537,922 shares of the company’s stock valued at $6,319,000 after purchasing an additional 1,474,560 shares during the period. Wasatch Advisors LP increased its position in shares of Nkarta by 37.4% during the 4th quarter. Wasatch Advisors LP now owns 2,520,909 shares of the company’s stock valued at $6,277,000 after purchasing an additional 686,229 shares during the last quarter. Finally, AWM Investment Company Inc. bought a new position in shares of Nkarta in the 4th quarter worth approximately $996,000. 80.54% of the stock is currently owned by hedge funds and other institutional investors.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.